Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Prim...
January 30 2020 - 7:07AM
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced a publication
in Movement Disorders detailing data on its novel NMDAr modulator,
NYX-458. The data demonstrate that administration of NYX-458
resulted in a reversal of cognitive deficits in a non-human primate
model of Parkinson’s disease. The data were published in the
January issue of Movement Disorders, the official journal of the
International Parkinson and Movement Disorder Society.
“This publication in Movement Disorders highlights the strength
of these data and underscores our commitment to advancing a novel
therapeutic option in a field with substantial medical need,” said
Norbert Riedel, Ph.D., president and chief executive officer of
Aptinyx. “Cognitive impairment is increasingly recognized as a
burdensome component of Parkinson’s and the few available therapies
are inadequate. In a highly translatable model, these data indicate
that the novel mechanism of NYX-458 can address aberrant
glutamatergic signaling underlying cognitive impairment in
Parkinson’s disease.”
In the published studies, NYX-458 exhibited rapid, robust, and
enduring reversal of the cognitive deficits induced in the
non-human primate model. The deficits induced in the model are
analogous to the attention, working memory, and executive function
impairments associated with dopamine loss in Parkinson’s disease
and are the predominant cognitive symptoms experienced by
Parkinson’s patients. The reversal of cognitive deficits—back to
healthy baseline levels on some measures—facilitated by NYX-458 was
observed as early as one-day following a single dose and lasted for
at least three weeks. Additionally, the positive effects were
recovered following re-impairment, maintained with repeat dosing,
and endured for up to three months following the last of the
repeated doses.
In a separate cohort of nun-human primates, NYX-458 did not
worsen motor symptoms associated with dopamine loss, did not
interfere with the anti-parkinsonian effects of levodopa, and did
not worsen the side effects of levodopa.
The reversal of cognitive deficits in these translatable disease
models suggests that NYX-458 has the potential to be a novel
therapeutic option for patients suffering from cognitive impairment
associated with Parkinson’s disease, and supports its continued
development.
About NYX-458NYX-458 is a novel oral NMDA
receptor modulator currently in clinical development for the
treatment of cognitive impairment associated with Parkinson’s
disease. NYX-458 has been shown to reverse cognitive deficits in
non-human primates in a model that is highly translatable to
Parkinson’s disease in humans. NYX-458 has also been shown to
improve cognitive performance across various other preclinical
models of neurodegeneration. In a Phase 1 clinical study, NYX-458
exhibited a favorable safety and tolerability profile across a wide
dose range and achieved CNS exposures consistent with exposures
observed at efficacious preclinical dose levels.
About AptinyxAptinyx Inc. is a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of proprietary synthetic small molecules for
the treatment of brain and nervous system disorders. Aptinyx has a
platform for discovery of novel compounds that work through a
unique mechanism to modulate—rather than block or
over-activate—NMDA receptors and enhance synaptic plasticity, the
foundation of neural cell communication. The company has three
product candidates in clinical development in central nervous
system indications, including chronic pain, post-traumatic stress
disorder, and cognitive impairment associated with Parkinson’s
disease. Aptinyx is also advancing additional compounds from its
proprietary discovery platform, which continues to generate a rich
and diverse pipeline of small-molecule NMDA receptor modulators
with the potential to treat an array of neurologic disorders. For
more information, visit www.aptinyx.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the company’s business plans and
objectives, including future plans or expectations for NYX-458,
therapeutic effects of the company’s product candidates,
expectations regarding the design, implementation, timing, and
success of its current and planned clinical trials, expectations
regarding its preclinical development activities, and expectations
regarding its uses and sufficiency of capital. Risks that
contribute to the uncertain nature of the forward-looking
statements include: the success, cost, and timing of the company’s
product candidate development activities and planned clinical
studies; the company’s ability to execute on its strategy;
regulatory developments in the United States and foreign countries;
as well as those risks and uncertainties set forth in the company’s
most recent annual report on Form 10-K and in its other filings and
reports with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Aptinyx
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Investor and Media Contact:Nick SmithAptinyx
Inc.ir@aptinyx.com or corporate@aptinyx.com847-871-0377
Source: Aptinyx Inc.
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Sep 2023 to Sep 2024